Abstract: SQL:1999 recursive queries are almost a quarter century old. In this standard the recursive queries have the form of recursive common table expressions. In recent years vendors of almost all ...

MiniMax Group Inc. shares surged in Hong Kong, buoyed by growing investor confidence in the technology offered by China’s generative AI startups. The stock gained as much as 30%, before closing up 25% ...

The MiniMax M2.5 is an advanced AI model designed to balance high performance with cost efficiency, as explained by Caleb Writes Code. Building on its predecessor, the M2.1, this model incorporates a ...

Recursive language models (RLMs) are an inference technique developed by researchers at MIT CSAIL that treat long prompts as an external environment to the model. Instead of forcing the entire prompt ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Andres Almiray, a serial open-source ...

MiniMax shares doubled in Hong Kong debut, beating rival Zhipu AI’s first-day gains. The IPO highlights China’s race to fund homegrown AI firms despite U.S. curbs on advanced chips. Rapid user growth ...

Every Wednesday and Friday, TechNode’s Briefing newsletter delivers a roundup of the most important news in China tech, straight to your inbox. Sign up Shares of MiniMax, an AI firm backed by Chinese ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

MiniMax Unveils M2.1 to Bring Multilingual Programming Gains to Open AI Models Your email has been sent Chinese AI startup’s release is a major update to its open-source model series, aimed at ...

What if the next big leap in AI wasn’t locked behind corporate paywalls but was instead freely available for anyone to explore, adapt, and innovate with? That’s exactly the promise of MiniMax M2.1, ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...